Benito’s Hat News Article in Today’s City AM

News of Benito’s Hat growth investment makes the headlines in this morning’s publication of City AM! Read more via the link below. Benito's Hat eyes expansion after securing new funding https://t.co/v7h7swSNAg pic.twitter.com/mbLFrPs6Vo — City A.M. (@CityAM) August 6, 2018

Mologic announces diagnostic clinical trial for Cystic Fibrosis

Calculus Capital portfolio company Mologic announced today that they have commenced a clinical trial to evaluate the company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients. The study aims to identify five urinary biomarkers associated with … Continued

Calculus invests £2m in Oxford BioTherapeutics

London, 3 August 2018: Calculus Capital has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised … Continued

Every1Mobile: Digital Health in International Development

Calculus Capital portfolio company Every1Mobile’s Head of Programme Design, Abi Gleek recently spoke at a DAI panel discussion on “Digital Health in International Development: Current Realities and Future Trends” in London. Abi shared insights from the U Afya programme in Nairobi, … Continued

Calculus invests £2m in CloudTrade

CloudTrade’s technology – which has been patented in Europe, the US and Australia – enables companies to automatically process electronic documents such as invoices and sales orders received by email. The software extracts information from a human-readable, machine-generated document, such … Continued

Axol Bioscience introduces Human iPSC-derived Atrial Cardiomyocytes

Calculus Capital portfolio company, Axol Bioscience Ltd., has launched their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease. As a human cell culture specialist they already provide custom services for … Continued